- Home
- SIBN vs CDXC Comparison
SIBN vs CDXC Comparison
Compare SIBN & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIBN
- CDXC
- Stock Information
- Founded
- SIBN 2008
- CDXC 1999
- Country
- SIBN United States
- CDXC United States
- Employees
- SIBN N/A
- CDXC N/A
- Industry
- SIBN Medical/Dental Instruments
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- SIBN Health Care
- CDXC Health Care
- Exchange
- SIBN Nasdaq
- CDXC Nasdaq
- Market Cap
- SIBN 547.3M
- CDXC 449.5M
- IPO Year
- SIBN 2018
- CDXC N/A
- Fundamental
- Price
- SIBN $17.84
- CDXC $5.42
- Analyst Decision
- SIBN Strong Buy
- CDXC Strong Buy
- Analyst Count
- SIBN 6
- CDXC 2
- Target Price
- SIBN $23.00
- CDXC $8.00
- AVG Volume (30 Days)
- SIBN 326.8K
- CDXC 338.3K
- Earning Date
- SIBN 02-24-2025
- CDXC 03-05-2025
- Dividend Yield
- SIBN N/A
- CDXC N/A
- EPS Growth
- SIBN N/A
- CDXC N/A
- EPS
- SIBN N/A
- CDXC 0.02
- Revenue
- SIBN $157,035,000.00
- CDXC $91,668,000.00
- Revenue This Year
- SIBN $21.89
- CDXC $18.64
- Revenue Next Year
- SIBN $16.65
- CDXC $20.72
- P/E Ratio
- SIBN N/A
- CDXC $275.46
- Revenue Growth
- SIBN 18.98
- CDXC 9.95
- 52 Week Low
- SIBN $11.70
- CDXC $1.48
- 52 Week High
- SIBN $20.60
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- SIBN 61.08
- CDXC 41.57
- Support Level
- SIBN $17.30
- CDXC $5.38
- Resistance Level
- SIBN $18.45
- CDXC $6.06
- Average True Range (ATR)
- SIBN 0.82
- CDXC 0.22
- MACD
- SIBN 0.00
- CDXC 0.00
- Stochastic Oscillator
- SIBN 74.58
- CDXC 5.88
About SIBN SI-BONE Inc.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.